Investment area
Bioindustrial Investments
Growth Investments
Region
North America
Date of investment
April 2022
Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The Company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species.
Contact
Marcus Remmers
Partner
Department: Bioindustrial Investments
Marcus joined Novo Holdings A/S in October 2022 as Partner in the Bioindustrials Team taking part in managing and developing the growing portfolio of investments.
Marcus has more than 25 years of experience with several senior leadership roles across the globe having worked in the US, Germany, Mexico, Austria and the UK. Previously, he was Chief Technology Officer at Royal DSM and prior to that held various positions in the Animal Health Industry including leadership of Biologics and Pharma R&D, global M&A licensing and Country President. Marcus is passionate about innovation and sustainability and also serves as a member of the Global Expert Network of the World Economic Forum.
Marcus holds a doctorate in Polymer Chemistry (1997) from the Max Planck Institute for Polymer Research and a Diploma in Chemistry from the University of Freiburg, Germany.
